Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: A role for pncA but not rpsA

Journal of Clinical Microbiology

Volumn 50, Issue 11, 2012, Pages 3726-3728

  Alexander, David C ^a,b   Ma, Jennifer H ^a   Guthrie, Jennifer L ^a   Blair, Joanne ^a   Chedore, Pam ^a   Jamieson, Frances B ^a,b  

^a PUBLIC HEALTH ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

AMPLICON; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERIUM ISOLATE; DNA SEQUENCE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PNCA GENE; PRIORITY JOURNAL; RPSA GENE; VARIABLE NUMBER OF TANDEM REPEAT;

AMIDOHYDROLASES; ANTITUBERCULAR AGENTS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS;

EID: 84867500613     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00620-12     Document Type: Article

References (11)

1. Becton Dickinson and Company. 2002. Bactec MGIT 960 PZA kit for the antimycobacterial susceptibility testing of Mycobacterium tuberculosis. Becton Dickinson and Company, Sparks, MD.
2. Chang KC, Yew WW, Zhang Y. 2011. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob. Agents Chemother. 55:4499-4505.
3. Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. 2010. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Clin. Microbiol. 48:300-301.
4. CLSI. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard - second edition. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Nguyen D, et al. 2003. Widespread pyrazinamide-resistant Mycobacterium tuberculosis family in a low-incidence setting. J. Clin. Microbiol. 41:2878-2883. (Pubitemid 36842274)
6. Scorpio A, Zhang Y. 1996. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2:662-667. (Pubitemid 26191953)
7. Shi W, et al. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333:1630-1632.
8. Simons SO, et al. 2012. Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Clin. Microbiol. 50:428-434.
9. Somoskovi A, et al. 2007. Sequencing of the pncA gene in members of the Mycobacterium tuberculosis complex has important diagnostic applications: identification of a species-specific pncA mutation in "Mycobacterium canettii" and the reliable and rapid predictor of pyrazinamide resistance. J. Clin. Microbiol. 45:595-599. (Pubitemid 46277031)
10. Stavrum R, Myneedu VP, Arora VK, Ahmed N, Grewal HM. 2009. In-depth molecular characterization of Mycobacterium tuberculosis from New Delhi - predominance of drug resistant isolates of the 'modern'(TbD1) type. PLoS One 4:e4540. doi:10.1371/journal.pone.0004540.
11. Sun Z, Scorpio A, Zhang Y. 1997. The pncA gene from naturally pyrazinamide resistant Mycobacterium avium encodes pyrazinamidase and confers pyrazinamide susceptibility to resistant M. tuberculosis complex organisms. Microbiology 143:3367-3373. (Pubitemid 27470186)